PA United imatinib imatinib resistant chronic myeloid leukemia blast phase clinical efficacy.docVIP

 PAGE \* MERGEFORMAT 10 PA United imatinib imatinib resistant chronic myeloid leukemia blast phase clinical efficacy OF: Barbara Lau, the Housing Bai Jun, Song Yongping, Zhang Li, Zhou Jian, Luo Changgeng [Abstract] Objective To observe the 12-acyl oxygen tetradecane phorbol 13 acetate (TPA) United imatinib imatinib resistant chronic myelogenous leukemia (CML) CML patients with clinical efficacy. Methods General dose of imatinib-resistant CML patients with acute in 12 cases, application of TPA combined with imatinib therapy, hematologic remission was observed rate of cytogenetic response rates and long-term survival. Results in 12 patients, 11 patients can be Clinical evaluation, including a complete hematologic remission rate of 36.36% (4 / 11), partial hematologic remission rate of 36.36% (4 / 11), the overall hematologic response rate was 72.72% (8 / 11), complete cytogenetic remission rate of 18.18% (2 / 11), partial cytogenetic response rate of 45.45% (5 / 11), the overall cytogenetic response rate was 63.64% (7 / 11). Conclusion TPA treatment combined conventional-dose imatinib imatinib resistant CML CML patients is feasible. [Keywords:] chronic myeloid leukemia, blast phase, 12-acyl oxygen tetradecane phorbol 13 acetate (TPA), imatinib (Gleevec), resistance Imatinib for chronic myeloid leukemia (chronic myeloid leukemia, CML) of patients had the role, is the treatment of CML in the first-line drugs. However, with the treatment of cases continues to increase, according to Ma imatinib resistance when the situation occur, particularly in patients with CML is more common. increasing the dose of imatinib can improve its efficacy, the use of the new tyrosine kinase inhibitors to overcome resistance to dasatinib Nicole, but both methods are expensive not suitable for China’s national conditions. Recently, we applied 12 acyl oxygen tetradecane phorbol 13 acetate (12 0 tetradecanoylphorbol 13 acetate, TPA) by combined conventional-dose imatinib treat